AIM IMMUNOTECH INC (AIM)
US00901B1052 - Common Stock
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Next safety cohort to begin escalated dosing soon...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner...
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner...
AIM ImmunoTech 宣布 Ampligen 与 Pembrolizumab 联合用药治疗复发性卵巢癌的研究取得积极顶线、方案计划中期报告数据
佛罗里达州奥卡拉, April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”）今日宣布了顶线中期数据，表明 Ampligen (rintatolimod) 和 Keytruda...
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that...
AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023
AIM stock results show that AIM ImmunoTech missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-value indications Company to host conference...
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will...
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET...
AIM ImmunoTech Announces Launch of CEO Corner Platform
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address...
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Phase 1b portion of the study expected to be completed within six months...
AIM stock dips amid mixed results for post-COVID fatigue therapy (NASDAQ:AGIO)
AIM ImmunoTechn (AIM) stock dipped after the company reported mixed topline results from a Phase 2 study of Ampligen for post-COVID fatigue. Read more here.
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is...
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
Subject enrollment is expected in Q1 2024...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands...
AIM ImmunoTech 宣布开展评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi® (durvalumab) 联合用药治疗胰腺癌疗效的 1b/2 期研究的开放招募
首次招募和首例受试者用药预计将很快将在荷兰罗特丹的 Erasmus Medical Center 进行 管理层在以下视频中对本公告及其意义进行了讨论，视频链接为：视频 奥卡拉，佛罗里达州, Jan. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国...
AIMイムノテック (AIM ImmunoTech)、膵臓がん治療を目的としたアストラゼネカ (AstraZeneca) のImfinzi® (デュルバルマブ) との併用によるAmpligen® (リンタトリモド) を評価する第Ib/II相試験の登録開始を発表
オランダ、ロッテルダムのエラスムス医療センター (Erasmus Medical Center) で、間もなく最初の登録および最初の被験者への投与を予定 経営陣による同発表とその意義についての説明は動画を参照されたい。 フロリダ州オカラ発, Jan. 11, 2024 (GLOBE NEWSWIRE)...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM ImmunoTech 获得两项重要美国专利，增强了 Ampligen® 的知识产权资产实力
Ampligen 治疗癌症和肌痛性脑脊髓炎 (ME)/慢性疲劳综合征 (CFS) 的某些美国独家权利延长至 2039 年 管理层在一段简短的视频中讨论了专利的颁发及其意义：点击此处 佛罗里达州奥卡拉, Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
AIMイムノテック (AIM ImmunoTech)、2つの重要な米国特許を取得し、Ampligen®の知的財産を強化
癌･ME/CFS治療薬Ampligenの米国における独占権を2039年まで延長 経営陣が特許の取得とその意味について簡単な動画で説明している。 こちら フロリダ州オカラ発 , Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief...